RxDoctor Payments Data

Ria Santos, MD

Family Medicine · Florence, KYNPI 1669611653

Payments from drug & device makers

$6,401in general payments, 2019–2025

Across 372 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$622
  • Lilly USA, LLC$467
  • Boehringer Ingelheim$356
  • Pfizer$351
  • Amgen$331
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,30198%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,401 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$54,560
Medicare patients
245
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin95$103,879
EliquisApixaban83$78,752
JanuviaSitagliptin Phosphate65$63,882
TradjentaLinagliptin48$45,897
MyrbetriqMirabegron51$40,527
OzempicSemaglutide23$36,725
MounjaroTirzepatide29$36,098
FarxigaDapagliflozin Propanediol19$21,791
Spiriva HandihalerTiotropium Bromide26$20,740
Breo ElliptaFluticasone/Vilanterol26$16,704
XareltoRivaroxaban20$15,465
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,337
EntrestoSacubitril/Valsartan11$7,365
BelsomraSuvorexant12$5,232
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$356$149,776143 claims
PfizerEliquis$351$78,75283 claims
MerckJanuvia, Belsomra$24$69,11477 claims
Astellas Pharma US IncMyrbetriq$265$40,52751 claims
Novo NordiskOzempic$622$36,72523 claims
Lilly USA, LLCMounjaro$467$36,09829 claims
GSKBreo Ellipta, Trelegy Ellipta$165$32,04146 claims
AstraZenecaFarxiga$249$21,79119 claims
Johnson & JohnsonXarelto$202$15,46520 claims
NovartisEntresto$64$7,36511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Florence

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →